The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Short Bowel Syndrome Clinical Trial

— DPP-4  

Official title:

The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02653131
• Other study ID #: GLP-1
• Status: Terminated
• Phase: Phase 4
• Start date: January 2016
• Est. completion date: April 2020

Study information

• Verified date: April 2020
• Source: Stanley Dudrick's Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Description:

The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: April 2020
• Est. primary completion date: April 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months

• stable metabolic status

• benign disease

Exclusion Criteria:

• HPN < 12 months

• metabolically unstable

• cancer as the reason for intestinal failure

Related Conditions & MeSH terms

• Short Bowel Syndrome
• Syndrome

Intervention

Drug:
• Dipeptidyl peptidase-4 inhibitor

Locations

Country	Name	City	State
Poland	Stanley Dudrick's Memorial Hospital	Skawina

Sponsors (1)

Lead Sponsor	Collaborator
Stanley Dudrick's Memorial Hospital

Country where clinical trial is conducted

Poland, 

References & Publications (1)

Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014 May;38(1 Suppl):45S-52S. doi: 10.1177/0148607114526241. Epub 2014 Mar 10. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of intestinal absorption	the use of DPP-4 inhibitor results in the better intestinal absorption	12 months